<DOC>
	<DOCNO>NCT01640834</DOCNO>
	<brief_summary>This study involve take single dose 100 mg 300 mg LY2409021 placebo ( inactive medicine ) take 3 capsule mouth . The study evaluate drug reduce amount insulin type 1 diabetic need 24 hour . This study include 7 day hospitalization period clinical research unit ( CRU ) involve screen within 30 day start study well telephone consultation within 5 day discharge CRU .</brief_summary>
	<brief_title>Study LY2409021 Participants With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Have type 1 diabetes mellitus ( T1DM ) base World Health Organization classification least 1 year daily insulin dose ≤1.5 international unit ( IU ) per kilogram ( kg ) body weight Have glycated hemoglobin A1c ( HbA1c ) great 9.0 % measure screening Have body mass index ( BMI ) ≥19.0 ≤35.0 kilogram per meter square ( kg/m^2 ) Have give write informed consent approve Lilly Received oral injectable medication intend treatment diabetes mellitus insulin 3 month prior screen Have 1 episode severe hypoglycemia within 3 month prior entry study , currently diagnose hypoglycemia unawareness Are pregnant intend become pregnant course study Women breastfeed Have history stroke , myocardial infarction , heart failure , unstable angina , coronary revascularization procedure within 6 month screen Have fast triglyceride &gt; 500 milligram per deciliter ( mg/dL ) ( 5.65 micromoles per liter [ mmol/L ] ) Have obvious clinical sign , symptom , laboratory evidence liver disease ( alanine transaminase [ ALT ] aspartate transaminase [ AST ] great 2 time upper limit normal screening ) Have history renal transplantation currently receive renal dialysis screen creatinine &gt; 2.0 mg/dL ( 177 micromoles per liter [ μmol/L ] ) Have disease , illness , condition ( include know diabetic autonomic neuropathy drug alcohol abuse psychiatric disorder ) within 6 month prior screen precludes participant follow completing study could increase risk hypoglycemia , accord investigator 's judgment Are currently enrol , complete , discontinue within last 30 day clinical trial involve offlabel use investigational drug device , concurrently enrol type medical research judge scientifically medically compatible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>